UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q
(Mark One)
[ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 1998
--------------------------------------------------
or
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from ______________________ to _____________________
Commission File Number: 0-21214
ORTHOLOGIC CORP.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
<TABLE>
<S> <C>
Delaware 86-0585310
- -------------------------------------------------------------------------------------------------------
(State of other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
</TABLE>
1275 W. Washington Street, Tempe, Arizona 85281
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
(602) 286-5520
- --------------------------------------------------------------------------------
(Registrant's telephone number, including area code)
- --------------------------------------------------------------------------------
(Former name, former address and former fiscal year,
if changed since last report)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. [X] Yes [ ] No
APPLICABLE ONLY TO CORPORATE ISSUERS:
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.
25,300,190 shares of common stock outstanding as of July 31, 1998
<PAGE>
ORTHOLOGIC CORP.
INDEX
Page No.
Part I Financial Information
Item 1. Financial Statements
Consolidated Balance Sheets
June 30, 1998 and December 31, 1997---------------------------- 1
Consolidated Statements of Operations
Three Months and Six Months ended June 30, 1998 and 1997------- 2
Consolidated Statements of Cash Flows
Six Months ended June 30, 1998 and 1997------------------------- 3
Notes to Consolidated Financial Statements------------------------ 4
Item 2. Management's Discussion and Analysis of
Financial Condition and Results of Operations------------ 9
Part II Other Information
Item 1. Legal Proceedings---------------------------------------- 12
Item 4. Submission of Matters to a Vote of Security Holders------ 12
Item 5. Other Information - Deadline for Shareholders Proposals-- 12
Item 6. Exhibits and Reports on Form 8-K------------------------- 13
<PAGE>
OrthoLogic Corp.
Consolidated Balance Sheets
(in thousands)
Unaudited
June 30, December 31,
1998 1997
--------- -----------
ASSETS
Cash and cash equivalents $ 788 $ 7,783
Short-term investments -- 4,569
Accounts receivable 25,114 34,424
Inventory 12,884 10,548
Prepaids and other current assets 1,602 1,673
Deferred income taxes 2,592 2,596
--------- ---------
Total current assets 42,980 61,593
Furniture, rental fleet and equipment 20,843 16,455
Accumulated depreciation (7,088) (4,934)
--------- ---------
Furniture and equipment, net 13,755 11,521
Intangibles, net 30,965 29,898
Deposits and other assets 1,138 91
--------- ---------
Total Assets $ 88,838 $ 103,103
========= =========
LIABILITIES AND STOCKHOLDERS' EQUITY
Liabilities
Accounts payable $ 3,581 $ 2,896
Loan payable - current portion 2,003 500
Obligations under co-promotion agreement 2,000 2,000
Accrued liabilities 9,129 11,340
--------- ---------
Total current liabilities 16,713 16,736
--------- ---------
Deferred rent and capital lease obligation -- 106
Loan payable - long term portion 238 524
Obligations under co-promotion agreement -- 1,000
--------- ---------
Total liabilities 16,951 18,366
--------- ---------
Stockholders' Equity
Common stock 13 13
Additional paid-in capital 119,653 119,413
Accumulated deficit (47,779) (34,689)
--------- ---------
Total stockholders' equity 71,887 84,737
--------- ---------
Total Liabilities and Stockholders' Equity $ 88,838 $ 103,103
========= =========
See notes to consolidated financial statements.
Page 1
<PAGE>
OrthoLogic Corp.
Consolidated Statement of Operations
(in thousands, except per share data)
Unaudited
<TABLE>
<CAPTION>
Three months ended June 30, Six months ended June 30,
--------------------------- -------------------------
1998 1997 1998 1997
---- ---- ---- ----
<S> <C> <C> <C> <C>
REVENUES $ 17,501 $ 18,317 $ 36,610 $ 35,619
COST OF REVENUES 4,203 4,578 8,619 9,324
---------------------- ----------------------
GROSS PROFIT 13,298 13,739 27,991 26,295
OPERATING EXPENSES
Selling, general and administrative 16,694 16,311 40,515 29,200
Research and development 545 613 1,043 1,189
Restructuring and other charges -- -- (399) --
---------------------- ----------------------
Total Operating Expenses 17,239 16,924 41,159 30,389
---------------------- ----------------------
OPERATING LOSS (3,941) (3,185) (13,168) (4,094)
OTHER INCOME
Grant revenue -- 25 -- 99
Interest income 40 389 137 951
---------------------- ----------------------
Total Other Income 40 414 137 1,050
---------------------- ----------------------
LOSS BEFORE TAXES (3,901) (2,771) (13,031) (3,044)
Provision for income taxes -- -- -- --
---------------------- ----------------------
NET LOSS (3,901) (2,771) (13,031) (3,044)
---------------------- ----------------------
BASIC EARNINGS PER SHARE
- ------------------------
NET LOSS PER COMMON WEIGHTED SHARES
OUTSTANDING (0.15) (0.11) (0.52) (0.12)
---------------------- ----------------------
WEIGHTED AVERAGE NUMBER OF COMMON SHARES
OUTSTANDING 25,293 25,096 25,276 25,066
---------------------- ----------------------
DILUTED EARNINGS PER SHARE
- --------------------------
NET LOSS PER COMMON AND DILUTED SHARES (0.15) (0.11) (0.52) (0.12)
---------------------- ----------------------
WEIGHTED SHARES OUTSTANDING 25,293 25,096 25,276 25,066
---------------------- ----------------------
</TABLE>
See notes to consolidated financial
statements
Page 2
<PAGE>
OrthoLogic Corp.
Consolidated Statements of Cash Flows
(in thousands)
Unaudited
<TABLE>
<CAPTION>
Six Months Ending June 30,
--------------------------
1998 1997
---- ----
<S> <C> <C>
OPERATING ACTIVITIES
Net Loss $(13,031) $ (3,044)
Non cash items:
Depreciation and amortization 3,913 3,078
Other -- (15)
Provision for bad debt 7,892 79
Net change in other operating items:
Accounts receivable (548) 445
Inventory (2,346) (610)
Prepaids and other current assets 75 (657)
Deposits and other assets (297) 2
Accounts payable 685 (496)
Accrued liabilities (2,201) (423)
-------- --------
Cash flows used in operating activities (5,858) (1,641)
-------- --------
INVESTING ACTIVITIES
Purchase of fixed assets (5,167) (2,797)
Cash paid for acquisitions, net of cash acquired (81) (20,907)
Investment in Chrysalis (750) --
Sales (Purchases) of short term investments 4,568 22,373
Collection of note receivable -- 200
Intangible from dealer transactions -- (486)
-------- --------
Cash flows used in investing activities (1,430) (1,617)
-------- --------
FINANCING ACTIVITIES
Payments on capital leases (402) (32)
Payments on loan payable 1,504 (295)
Payments under co-promotion agreement (1,000) (1,011)
Proceeds from issuance of common stock -- --
Foreign exchange (49) --
Net proceeds from stock option exercises 240 148
-------- --------
Cash flows used in financing activities 293 (1,190)
-------- --------
NET DECREASE IN CASH AND CASH EQUIVALENTS (6,995) (4,448)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 7,783 13,494
-------- --------
CASH AND CASH EQUIVALENTS, END OF PERIOD $ 788 $ 9,046
======== ========
</TABLE>
See notes to consolidated financial statements.
Page 3
<PAGE>
ORTHOLOGIC CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Financial Statement Presentation
--------------------------------
The consolidated financial statements have been prepared in accordance with
generally accepted accounting principles and include accounts of the
Company and its subsidiaries. All significant intercompany accounts and
transactions have been eliminated.
The consolidated balance sheet as of June 30, 1998, and the consolidated
statements of operations and cash flows for the six months ended June 30,
1998 and 1997 are unaudited, however, in the opinion of management, include
all adjustments (consisting only of normal recurring adjustments) necessary
for the fair presentation of the financial position, results of operations
and cash flows. The results of operations for the interim periods are not
necessarily indicative of the results to be expected for the complete
fiscal year. The Balance Sheet as of December 31, 1997 is derived from the
Company's audited financial statements included in the 1997 annual report.
It is suggested that these financial statements be read in conjunction with
the financial statements and notes thereto included in the company's 1997
Annual Report.
2. Acquisition
-----------
On March 3, 1997 and March 12, 1997, the Company acquired certain assets
and assumed certain liabilities of Toronto Medical Corp. ("Toronto") and
Danninger Medical Technology, Inc. ("DMTI"). After paying certain of the
assumed liabilities, the net cash outlay was approximately $7.2 million for
Toronto and $11 million for DMTI. Both acquisitions were accounted for as a
purchase which resulted in goodwill of $4 million for Toronto and $7.7
million for DMTI. The goodwill is being amortized over 20 years.
Had the Toronto and DMTI acquisitions occurred on January 1, 1997, combined
unaudited pro forma results for the six months ended June 30, 1997 would
have been $37.5 million net revenues, ($3.4 million) net earnings (loss),
and (.14) net earnings (loss) per common share. The operations were fully
integrated in the Company's financial statements for 1998.
3. Co-promotion Agreement
----------------------
The Company entered into an exclusive, co-promotion agreement (the
"Agreement') with Sanofi Pharmaceuticals, Inc. ("Sanofi") on June 23, 1997
for the purpose of marketing Hyalgan, a hyaluronic acid sodium salt, to
orthopedic surgeons in the United States for the treatment of pain in
patients with osteoarthritis of the knee. The initial term of the agreement
ends on December 31, 2002. Upon the expiration of the initial term, Sanofi
may terminate the agreement, extend the agreement for an additional one
year period, or enter into a revised agreement with the Company. Upon
termination of the Agreement,
Page 4
<PAGE>
Sanofi must pay the Company an amount equal to 50% of the gross
compensation paid to the Company, pursuant to the Agreement, for the
immediately preceding year.
The Company is paid a commission which is based upon the number of units
sold at the wholesale acquisition costs less amounts for distribution
costs, discounts, rebates and returns. In addition, the Company is
obligated: to use its best efforts to market and promote Hyalgan; to pay
Sanofi a royalty of 10% of the net selling price, as defined; and to pay
the manufacturer of Hyalgan a product transfer price and a pro-rata portion
of a 10% royalty on combined annual net sales of Hyalgan by Sanofi and the
Company in excess of $30 million. In addition, the Company is obligated to
pay a total of $4.0 million during the first eighteen months of the
agreement. During 1997 and the first six months of 1998, the Company paid
$2.0 million of this amount. The Company has recorded the remaining $2.0
million as a liability in its financial statements.
The Company's sales force began to promote Hyalgan in the third quarter of
1997.
4. Licensing Agreement
-------------------
The Company announced in January 1998 that it had acquired a minority
equity interest in a biotech firm, Chrysalis BioTechnology, Inc. for
$750,000. As part of the transaction, the Company has been awarded a
nine-month world-wide exclusive option to license the orthopedic
applications of Chrysalin, a patented 23-amino acid peptide that has shown
promise in accelerating the healing process. Chrysalis is currently
developing the technology to stimulate the skin-wound healing process and
has completed an extensive pre-clinical safety and efficacy profile of the
product. In pre-clinical animal studies, Chrysalin was also shown to double
the rate of fracture healing with a single injection into the fresh
fracture gap. The Company's agreement with Chrysalis contains provisions
for the Company to continue and expand its option to license Chrysalin
contingent upon regulatory approvals, successful pre-clinical trials, and
certain trials and certain milestone payments to Chrysalis by the Company.
The Company will pursue commercialization of Chrysalis, initially seeking
Food and Drug Administration (FDA) approval for the human clinical trials
for the fracture-healing indication. The Company projects that Chrysalis
could receive all the necessary FDA approvals and be introduced in the
market during 2000. There can be no assurance, however, that the clinical
trials will result in favorable data or that FDA approvals, if sought, will
be obtained.
5. Litigation
----------
During 1996, certain lawsuits were filed in the United States District
Court for the District of Arizona against the Company and certain officers
and directors, alleging violations of Section 10(b) of the Securities
Exchange Act of 1934 and SEC Rule 10b-5 promulgated thereunder.
Plaintiffs in these actions allege that correspondence received by the
Company from the FDA regarding the Company's OrthoLogic 1000 Bone Growth
Stimulator was material and undisclosed, leading to an artificially
inflated stock price. Plaintiffs further alleged
Page 5
<PAGE>
that practices referenced in the correspondence operated as a fraud against
plaintiffs and that once the FDA letter became known, a material decline in
the stock price of the Company occurred, causing damage to the plaintiffs.
All plaintiffs seek class action status, unspecified compensatory damages,
fees and costs. Plaintiffs also seek extraordinary, all equitable and/or
injunctive relief as permitted by law. The actions were consolidated for
the purposes in the United States District court for the District of
Arizona and lead plaintiffs and counsel were appointed. The Company and its
officers and directors moved to dismiss the consolidated amendment
complaint for failure to state a claim. The Court dismissed the
consolidated amended complaint in its entirety against the Company and its
officers and directors, but gave plaintiffs leave to amend all claims to
cure all deficiencies. An amended complaint was filed in April 1998, and
the Company has moved again to dismiss the amended complaint on virtually
the same grounds as it did before.
In addition, the Company has been served with a substantially similar
action filed in Arizona State Court alleging state law causes of action
grounded in the same set of facts. This action remains stayed pending
further developments in the Federal action.
In addition to the foregoing, a shareholder derivative complaint alleging,
among other things, breach of fiduciary duty in connection with the conduct
alleged in the aforesaid federal and state court class actions, have also
been filed in Arizona State Court. That action remains stayed pending
further developments in the Federal consolidated class action.
In March 1998, the former owner of the CPM assets acquired in the DMTI
acquisition filed a lawsuit in the Court of Common Pleas in Franklin
County, Ohio against the Company. The plaintiff alleges that the Company
breached the acquisition agreement by not satisfying certain liabilities it
assumed in the acquisition and that the Company breached an ancillary
agreement for the temporary provision of services following the
acquisition. Plaintiff has also demanded from the Court of Common Pleas a
declaration that the Company is not entitled to cash escrowed in the
acquisition. The Company had previously requested delivery to it of the
escrowed cash and demanded indemnification for the plaintiff's breaches of
representations and warranties in the acquisition agreement. The costs
associated with defending these allegations and the potential outcome
cannot be determined at this time and, accordingly, no estimate for such
costs have been included in these financial statements.
Management believes that the allegations are without merit and will
vigorously defend them.
At June 30, 1998, the Company is involved in various other legal
proceedings that arose in the ordinary course of business. In management's
opinion, the ultimate resolution of these other legal proceedings will not
have a material affect on the financial position, results of operations, or
cash flow of the Company.
Page 6
<PAGE>
6. New Accounting Pronouncements
-----------------------------
Effective January 1, 1998, the Company adopted Statement of Financial
Accounting Standard No. 130 "Reporting Comprehensive Income." For the six
month period and the quarter ended June 30, 1998, net income approximated
comprehensive income.
7. Debt
----
The Company has a revolving line of credit agreement with Silicon Valley
bank for $7.5 million. At June 30, 1998, the outstanding balance was $1.5
million.
8. Allowance for Doubtful Accounts
-------------------------------
The allowance for doubtful accounts was increased by approximately $9.3
million during the first quarter of 1998, over and above the normal
quarterly activity. The increase was a result of a management decision to
focus resources on collection of current sales and on re-engineering the
overall process of billing and collections. It is no longer considered to
be cost effective to expend significant resources on the collection of the
older receivables as had been done in the past.
9. Label Change for the OL 1000
----------------------------
The Company has received approval for its PMA (Pre-Market Approval)
Supplement from the FDA to change the label for the OL 1000 Bone Growth
Stimulator. The revised label states that the OL 1000 is safe and effective
for use in treating non-union fractures. A fracture is considered non-union
when the fracture site shows no visibly progressive signs of healing. The
former reference on the label to the nine-month post-injury time frame has
been removed. OL 1000s may now be prescribed when the physician determines
that a non-union exists.
10. Equity Placement
----------------
Subsequent to June 30, 1998, it was announced that the Company has
completed a private equity placement with two investors, an affiliate of
Credit Suisse First Boston Corp. and Capital Ventures International. Under
the terms of the Purchase Agreement, OrthoLogic sold 15,000 shares of
Series B Convertible Preferred Stock for $15 million (prior to costs). The
Series B Convertible Preferred Stock is convertible into shares of Common
Stock 300 days after issuance and will automatically convert, to the extent
not previously converted, into Common Stock four years following the date
of issuance. Each share of Series B Convertible Preferred Stock is
convertible into Common Stock at a per share price equal to the lesser of
the average of the 10 lowest closing bids during the 30 days prior to
conversion, and 103% of the average of the closing bids for the 10 days
prior to the 300th day following the issuance. The Series B Convertible
Preferred Stock is convertible into Common Stock prior to the 300th day
after issuance upon the occurrence of certain events (in which case the
conversion price will be the average of the 10 lowest closing bids during
the 30 days prior to conversion). This Agreement contains strict
Page 7
<PAGE>
covenants that protect against hedging and short-selling of OrthoLogic
Common Stock while the purchaser holds shares of the Series B Convertible
Preferred Stock.
In connection with the private placement of the Series B Convertible
Preferred Stock, OrthoLogic issued to the purchasers warrants to purchase
40 shares of Common Stock for each share of Series B Convertible Preferred
Stock, exercisable at $5.50. The warrants are valued at $1,093,980. The
cost of the Equity Offering was approximately $966,000. Both the value of
the warrants and the cost of the equity offering will be recognized over
the 10 month conversion period as an "accretion of non-cash Preferred Stock
Dividends" for the amount of $617,994 per quarter. The Company has agreed
to file a registration statement covering the underlying Common Stock.
Proceeds from the private placement will be used to fund new product
opportunities, including SpinaLogic, Chrysalin and Hyalgan, as well as to
complete the re-engineering of the Company's key business processes.
Page 8
<PAGE>
MANAGEMENT'S DISCUSSIONS AND ANALYSIS OF FINANCIAL
CONDITIONS AND RESULTS OF OPERATIONS
The following is management's discussion of significant factors that affected
the Company's interim financial condition and results of operations. This should
be read in conjunction with Management's Discussion and Analysis of Financial
Condition and Results of Operations included in the Company's Annual Report on
Form 10-K for the year ended December 31, 1997.
Results of Operations
Revenues
OrthoLogic reported revenues of $17.5 million for the second quarter,
representing a 4.4% decrease from revenues of $18.3 million for the second
quarter of 1997. OrthoLogic's revenues increased 2.8% to $36.6 million from
$35.6 million for the six months ended June 30, 1998.
Gross Profit
Gross profit increased from $26.3 million for the six months ended June 30, 1997
to $28.0 million for the six months ended June 30, 1998. Gross profit, as a
percentage of revenue, was 76% for the six months ended June 30, 1998 compared
to 74% for the comparable period during 1997.
Selling, General and Administrative Expenses
Selling, general and administrative (SG&A) expenses for the six months ended
June 30, 1998 were $41.2 million, up $10.7 million from the comparable period in
1997. The increase from 1997 is due in part to the variable costs associated
with the increased revenue. The first quarter of 1998 also included an increase
of $9.3 million in the allowance for doubtful accounts over the normal quarterly
provision. As part of a larger project to re-engineer the sales, billings and
collections process for enhanced efficiencies, the Company obtained an
independent evaluation of its billing files and collection strategies in April
of 1998. The information obtained from this study prompted management to change
its focus for future collection efforts to be primarily on the more recent
sales. The cost of continuing to manage the older accounts receivable to the
extent that had been done in the past was no longer considered as cost effective
for the Company. This shift in the emphasis for the collections policy prompted
the Company to increase the bad debt reserve for the outstanding balances of the
older receivables.
Page 9
<PAGE>
Research and Development
Research and Development (R&D) expenses were $1.0 million for the six months
ended June 30, 1998 compared to $1.2 million for the comparable 1997 period. The
decrease was due to the unveiling of a new, single coil version of the OL-1000,
no longer in R&D. The device extends the fracture healing benefits of the
OL-1000 to the thigh and the long bone of the upper arm, extending from the
shoulder to the elbow, and is suitable for treating non-union fractures in most
areas for larger individuals.
Other Income and Expenses
Other income declined to $137,000 in the six months ending June 30, 1998 from $1
million during the same period in 1997. This decrease is attributed to: (1) the
Company not participating in any research grant projects in the current year;
and (2) a reduction in cash and investments, which has yielded a reduction in
interest income earned to $137 thousand in 1998, from $951 thousand in 1997.
Liquidity and Capital Resources
On June 30, 1998, the Company had cash and investments of $790,000 compared to
$12.3 million (including short-term investments) at December 31, 1997. The
decrease in cash and investments is primarily the result of a $1 million payment
under a co-promotion agreement, a $2.3 million increase in inventory, and a $2.2
million increase in fixed assets (net of depreciation), mostly for the Ortho
Rehab rental fleet business. In addition, in January, OrthoLogic acquired a
$750,000 equity stake in pioneering biotech firm, Chrysalis BioTechnology, Inc.
in Galveston, Texas. Cash used for operations amounted to $5.8 million during
the six month period. A portion of operation costs included strengthening the
senior management team, reorganizing the field sales force, redesigning business
processes and renewing emphasis on product development. Cash increased by
accessing a line of credit for $1.5 million. The line of credit was paid off
subsequent to the period end.
The Company anticipates that its cash on hand and the funds available from the
line of credit will be sufficient to meet the Company's presently projected cash
and working capital requirements for the next 12 months. There can be no
assurance, however, that this will prove to be the case. If the Company were
required to obtain additional financing in the future, there can be no assurance
that such sources of capital will be available on terms favorable to the
Company, if at all.
Year 2000 Compliance
The inability of computers, software and other equipment utilizing
microprocessors to recognize and properly process data fields containing a 2
digit year is commonly referred to as the Year 2000 Compliance issue. As the
year 2000 approaches, such systems may be unable to accurately process certain
date-based information.
Page 10
<PAGE>
The Company has identified all significant applications that will require
modification to ensure Year 2000 Compliance. Internal and external resources are
being used to make the required modifications and test Year 2000 Compliance. The
modification process of all significant applications is substantially complete.
The Company plans on completing the testing process of all significant
applications by December 31, 1998.
In addition, the Company has communicated with others whom it does significant
business to determine their Year 2000 Compliance readiness and the extent to
which the Company is vulnerable to any third party Year 2000 issues. However,
there can be no guarantee that the systems of other companies on which the
Company's systems rely will be timely converted, or that a failure to convert by
another company, or a conversion that is incompatible with the Company's
systems, would not have a material adverse effect on the Company.
The total cost to the Company of these Year 2000 Compliance activities has not
been and is not anticipated to be material to its financial position or results
of operations in any given year. These costs and the date on which the Company
plans to complete the Year 2000 modification and testing processes are based on
management's best estimates, which were derived utilizing numerous assumptions
of future events including the continued availability of certain resources,
third party modification plans and other factors. However, there can be no
guarantee that these estimates will be achieved and actual results could differ
from those plans.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
Certain of the statements contained in this document that are not historical
facts, including, without limitation, statements of future expectations,
projections of results of operations and financial condition, statements and
future economic performance and other forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, are subject to
known and unknown risks, uncertainties and other factors which may cause the
actual results, performance or achievement of the Company to differ materially
from those contemplated in such forward-looking statements. In addition to the
specific matters referred to herein, important factors which may cause actual
results to differ from those contemplated in such forward-looking statements
include: (i) the results of the Company's efforts to implement in business
strategy; (ii) actions of the Company's competitors and the Company's ability to
respond to such actions; (iii) changes in governmental regulation, tax rates and
similar matter; (iv) other risks detailed in the Company's other filings with
the Commission; and (v) the costs and results of pending litigation.
Page 11
<PAGE>
Part II - OTHER INFORMATION
Item 1. Legal Proceedings
See "Note 5 - Litigation" of the Notes to Consolidated Financial
Statements above.
Item 2. Changes in Securities and Use of Proceeds
See Note 10 of the Notes to Consolidated Financial Statements above.
Item 4. Submission of Matters to Vote of Security Holders
The annual meeting of the stockholders of the Company was held on May
15, 1998 to vote on: the election of Class I Directors (Proposal 1);
an amendment to the Company's 1997 Stock Option Plan to increase the
number of shares of common stock available for grant thereunder by
375,000 shares (Proposal 2); and the ratification of Deloitte &
Touche LLP as independent accountants for the fiscal year ending
December 31, 1998 (Proposal 3). The results are as follows:
BROKER
NON-
FOR AGAINST ABSTAINED VOTES
Proposal 1
Fredric J. Feldman 23,649,127 309,343 0 0
Thomas R. Trotter 23,658,974 299,496 0 0
Proposal 2 22,59,510 1,233,266 125,694 0
Proposal 3 23,825,291 52,465 80,714 0
A more detailed discussion of each proposal is included in the
Company's Proxy Statement for the 1998 Annual Meeting of
Stockholders.
Item 5. Other Information
Deadline for Shareholders Proposals
Pursuant to Rule 14a05(e) under the Securities Exchange Act of 1934,
as amended, effective June 29, 1998:
(1) The deadline for submitting shareholder proposals for inclusion
in the Company's proxy statement and for proxy for the Company's
1999 annual
Page 12
<PAGE>
meeting of shareholders pursuant to Rule 14a-8 is December 8,
1998.
(2) The date after which notice of a shareholder proposal submitted
outside the processes of Rule 14a-8 is considered untimely is
February 23, 1999.
Item 6. Exhibits and Reports
(a) See Exhibit Index following the Signatures page, which is
incorporated herein by reference.
(b) Reports on Form 8-K
1. On July 13, 1998, the Company issued 15,000 shares of its
Series B Convertible Preferred Stock and related Warrants in
a private placement to two institutional investors. The
Company estimates the net proceeds of the offering, after
expenses, to be approximately $14 million. The Company has
agreed to prepare and file with the Securities and Exchange
Commission a registration statement covering the resale of
the shares of Common Stock issuable pursuant to the terms of
the Series B Stock and related Warrants. The Securities
Purchase Agreement, Certificate of Designation, Warrants,
and Registration Rights Agreement were filed as exhibits to
the Form 8-K.
2. On July 13, 1998, OrthoLogic Corp. issued a Press Release
regarding the previously mentioned private placement of
15,000 shares of its Series B Convertible Preferred Stock
and related Warrants. The press release was filed as an
exhibit to a report on Form 8-K.
Page 13
<PAGE>
ORTHOLOGIC CORP.
EXHIBIT INDEX TO QUARTERLY REPORT ON FORM 10-Q
FOR THE QUARTERLY PERIOD ENDED JUNE 30, 1998
Exhibit Incorporated by Filed
No. Description Reference to: Herewith
--- ----------- ------------- --------
27 Financial Data Schedule
Page 14
<PAGE>
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ORTHOLOGIC CORP.
- ----------------
(Registrant)
<TABLE>
<CAPTION>
Signature Title Date
- --------- ----- ----
<S> <C> <C>
/s/ Thomas R. Trotter President and Chief Executive Officer August 7, 1998
- ------------------------- (Principal Executive Officer)
Thomas R. Trotter
/s/ Terry D. Meier Sr. Vice-President and Chief Financial Officer August 7, 1998
- ------------------------- (Principal Financial and Accounting Officer)
Terry D. Meier
</TABLE>
Page 15
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
financial statements in OrthoLogic Corporation's report on Form 10-K for the
year ended December 31, 1997 and is qualified in its entirety by reference to
such financial statements.
</LEGEND>
<CURRENCY> U.S. Dollars
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> DEC-31-1998
<PERIOD-START> JAN-01-1998
<PERIOD-END> JUN-30-1998
<EXCHANGE-RATE> 1
<CASH> 787,530
<SECURITIES> 0
<RECEIVABLES> 43,179,735
<ALLOWANCES> 18,356,735
<INVENTORY> 12,884,290
<CURRENT-ASSETS> 42,979,506
<PP&E> 13,755,158
<DEPRECIATION> 7,088,197
<TOTAL-ASSETS> 88,837,837
<CURRENT-LIABILITIES> 16,712,508
<BONDS> 0
0
0
<COMMON> 12,649
<OTHER-SE> 71,874,671
<TOTAL-LIABILITY-AND-EQUITY> 88,837,837
<SALES> 10,127,416
<TOTAL-REVENUES> 36,610,107
<CGS> 1,685,578
<TOTAL-COSTS> 41,147,010
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (13,031,161)
<INCOME-TAX> (196)
<INCOME-CONTINUING> (13,030,935)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (13,030,936)
<EPS-PRIMARY> (0.52)
<EPS-DILUTED> (0.52)
</TABLE>
